ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

Conference9MW2821Neutral

AI Analysis

Summary

Mabwell (688062.SH, 02493.HK) will present Phase II clinical data at ESMO 2026 for its Nectin-4-targeting ADC 9MW2821 (bulumtatug fuvedotin) in ADC-pretreated triple-negative breast cancer. The excerpt does not disclose any results.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Mabwell will present Phase II clinical data for 9MW2821 (BFv) in ADC-pretreated triple-negative breast cancer at ESMO 2026; no results disclosed in the excerpt.

Importance:4/10

Sentiment:

0.20

ESMO 2026ADCNectin-4triple-negative breast cancerPhase 2oncologyconference presentation

Related Companies

$INBP

Read the original article

Published by PR Newswire Biotech on October 19, 2026 2:00 AM

Read Original